Skip to main content
eScholarship
Open Access Publications from the University of California

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

  • Author(s): Bivona, Trever
  • Zhang, Z
  • Lee, JC
  • Lin, L
  • Olivas, V
  • Au, V
  • Laframboise, T
  • Abdel-Rahman, M
  • Wang, X
  • Levine, AD
  • Rho, JK
  • et al.

Published Web Location

http://europepmc.org/articles/PMC3408577?pdf=render
No data is associated with this publication.
Abstract

Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance. Secondary mut

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item